Bioventure, a subsidiary of our Healthcare Division, GlobalOne Healthcare Holding (GHH), has signed an exclusive licensing agreement with Cooper Pharma S.A. (Cooper) for Adalimumab. This agreement provides Cooper with exclusive rights to register, hold the marketing authorisation, and commercialise Adalimumab in Morocco.

Bioventure, which specialises in biosimilars and speciality generics, in/out-licensing, tech transfer, and investment in disruptive healthtech, medtech and biotechnology solutions, is currently the Middle East and Africa’s exclusive license holder for a biosimilar portfolio developed and manufactured by Alvotech, an Iceland-based pharmaceutical company.

Alvotech’s Adalimumab has recently been granted European Medicines Agency (EMA) approval for concentration 100mg/mL.

Murshed Al Redaini, Group Chief Executive Officer of Yas Holding, said: “By forging a strategic partnership in Morocco, we are investing in the future and growth of the region’s healthcare industry, while ensuring a stable supply of affordable biopharmaceuticals. This aligns with our vision to continuously improve access to quality healthcare and strengthen our ongoing investments.”

Bioventure is a subsidiary of GlobalOne Healthcare Holding which has recently expanded its strategic investment in Iceland-based biopharmaceutical company Alvotech. It is expected to introduce biologic technology and transform the region’s healthcare industry.

Ashraf Radwan, CEO of GlobalOne Healthcare Holding said: “We are excited to partner with Cooper Pharma to bring advanced medical products to Morocco which currently has limited access to affordable biosimilars. The next step is to explore the potential for local manufacturing, as part of our strategy to invest in the region’s global life sciences and disruptive health tech.”

Ayman Cheikh Lahlou, CEO of Cooper Pharma, said: “We are excited to start this partnership with Bioventure on Adalimumab. It is a great opportunity for us to expand our biosimilar portfolio. Part of our mission is to provide Moroccan patients with high-quality and accessible Adalimumab biosimilars. We are exploring future opportunities with Bioventure to improve the quality of life of Moroccan and African patients.”

Adalimumab is a monoclonal antibody that is used to treat rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn’s disease, ulcerative colitis, psoriasis, hidradenitis suppurativa, uveitis, and juvenile idiopathic arthritis. It is available for administration in two forms: autoinjector and pre-filled syringe.

Adalimumab was approved for medical use in the United States in 2002 and is on the World Health Organization’s List of Essential Medicines.